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Abstract
Background: No clear consensus has been reached on the alpha-adducin polymorphism (Gly460Trp) and essential
hypertension risk. We performed a meta-analysis in an effort to systematically summarize the possible association.
Methodology/Principal Findings: Studies were identified by searching MEDLINE and EMBASE databases complemented
with perusal of bibliographies of retrieved articles and correspondence with original authors. The fixed-effects model and
the random-effects model were applied for dichotomous outcomes to combine the results of the individual studies. We
selected 22 studies that met the inclusion criteria including a total of 14303 hypertensive patients and 15961 normotensive
controls. Overall, the 460Trp allele showed no statistically significant association with hypertension risk compared to Gly460
allele (P=0.69, OR=1.02, 95% CI 0.94–1.10, Pheterogeneity,0.0001) in all subjects. Meta-analysis under other genetic contrasts
still did not reveal any significant association in all subjects, Caucasians, East Asians and others. The results were similar but
heterogeneity did not persist when sensitivity analyses were limited to these studies.
Conclusions/Significance: Our meta-analysis failed to provide evidence for the genetic association of a-adducin gene
Gly460Trp polymorphism with hypertension. Further studies investigating the effect of genetic networks, environmental
factors, individual biological characteristics and their mutual interactions are needed to elucidate the possible mechanism
for hypertension in humans.
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Introduction
Essential hypertension (EH) is a major global public health
problem which affects a large proportion of adult population
worldwide.Theoccurrence anddevelopmentofEHareregarded as
a complex multifactorial disorder resulted from genetic and
environmental factors, as well as their interactions [1]. Although
substantial contribution has been made to unravel the pathophys-
iological mechanisms of hypertension, the molecular genetics of EH
is stillan intricate and mysteriousfield.Approximately,20% to 60%
of the population variability in blood pressure (BP) is genetically
determined [2]. As a consequence, it is necessary to explore etiology
from many of the genes susceptible to hypertension.
Adducin is a ubiquitously expressed heterodimeric cytoskeleton
protein composed of two subunits (a-subunit and either b-o rc-
subunit) which are encoded by three genes (ADD1, ADD2 and
ADD3, respectively) located on different chromosomes [3].
Previous studies in the Milan hypertensive rat strain model of
hypertension and humans proved that an altered adducin function
might cause hypertension through an enhanced constitutive
tubular sodium reabsorption [4]. At the molecular level, the role
of alpha-adducin (ADD1) in hypertension and other cardiovascu-
lar diseases has been extensively evaluated, paying particular
attention to the rs4961 (Gly460Trp, G460W or G460T) single
nucleotide polymorphism (SNP) at exon 10 on chromosome
4p16.3 [5], in which a guanine-to-thymine transversion at
nucleotide 614 leads to a glycine (Gly) to tryptophan (Trp)
substitution at amino acid position 460. In clinical studies, some
have reproduced the supportive association between Gly460Trp
polymorphism and EH or blood pressure (BP) level [6–9], whereas
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e13057others were unable to replicate these findings [10–14]. Although a
series of relevant research were carried out on the relationship of
this polymorphism to hypertension risk across different nations,
the results were still fairly confusing rather than conclusive and
showed strong racial and regional variations. Given the accumu-
lation of data, we have conducted a formal meta-analysis from all
eligible case-control studies published to date, in order to clarify
the role of Gly460Trp polymorphism in hypertension.
Materials and Methods
Identification and eligibility of relevant studies
To identify all studies that examined the association of alpha-
adducin Gly460Trp polymorphism with hypertension, we con-
ducted a systematic computerized literature search of PubMed and
EMBASE databases (up to May 2010) using the following various
combinations of keywords and subject terms: ‘adducin’ OR
‘ADD’, ‘polymorphism’ AND ‘hypertension’. We also retrieved
additional studies through the MEDLINE option ‘related articles’.
Search results were limited to articles in English and studies on
human subjects without country restrictions. Only research articles
were included. When studies from the same research group with
overlapped population were found, only the one with larger
population was included to avoid data duplication. The full text of
the retrieved articles was scrutinized to decide whether informa-
tion on the topic of interest was included. References of the
retrieved publications were screened. If an article reported results
on different ethnicity subpopulations, each subpopulation was
treated as a separate study in our meta-analysis. Studies included
in the meta-analysis had to meet all the following criteria: (a) using
an unrelated case–control design (a retrospective, cross-sectional,
or prospective study design), (b) have available genotype
frequency, (c) genotype distribution of control population must
be consistent with Hardy–Weinberg equilibrium (HWE). Hyper-
tension was defined as systolic BP (SBP) $140 mmHg and/or
diastolic BP (DBP) $90 mmHg and/or treatment with anti-
hypertensive medication.
Data extraction
In order to extract the information needed, all articles were
reviewed and separately collated by two independent investigators
(K.L., J.L.) who checked for any discordance and reached a
consensus. If they could not come to an agreement, a third one
adjudicated the disagreements. The following information was
collected on the genotype of Gly460Trp according to different
kinds of ethnicities. First author, year of publication, country and
racial descent of the subjects included, study design and
characteristics were described in Table S1. Diagnostic standard
of each study, sample sizes of cases and controls, genotype
numbers, allele frequency in both cases and controls, and P values
of HWE in controls were summarized in Table S2.
Statistical analysis
The strength of the association of Gly460Trp with hyperten-
sion was measured by odds ratio (OR) corresponding to 95%
confidence interval (CI) which was calculated according to the
method of Woolf [15]. We examined the association between Trp
allele of alpha-adducin Gly460Trp and hypertension risk (Trp vs.
Gly), the dominant genetic model (GlyTrp+TrpTrp vs. GlyGly),
the recessive genetic model (TrpTrp vs. GlyTrp+GlyGly), and
homozygote comparison (TrpTrp vs. GlyGly). In our study, two
models of meta-analysis were applied for dichotomous outcomes
in Review-Manager 4.2 software: the fixed-effects model and the
random-effects model. The fixed-effects model using the Mantel–
Haenszel method, assumes that studies are sampled from
populations with the same effect size, making an adjustment to
the study weights according to the in-study variance. The
random-effects model using the DerSimonian and Laird’s
method, which assumes that studies are taken from populations
with varying effect sizes, calculating the study weights both from
in-study and between-study variances, considering the extent of
variation, or heterogeneity. We performed a chi-square-based Q
statistic test to assess the between-study heterogeneity [16].
Heterogeneity was considered significant for p,0.10 because of
the low power of the statistic. The inconsistency index I
2 was also
calculated to evaluate the variation which was caused by
heterogeneity rather than by chance, and higher values of the
index indicate the existence of heterogeneity [17]. The fixed-
effects model (if p.0.10) or the random-effects model (if p,0.10)
was used to pool the results [18]. The significance of the pooled
OR was determined by the Z test and a P value of ,0.05 was
considered significant. Studies were also categorized into
subgroups based on ethnicity. For each genetic comparison,
subgroup analyses were considered for the population of
Caucasians, East Asians and others to estimate ethnic-specific
OR. The subgroup ‘others’ included the South African Negro
population and African-American population. In addition, in
order to further uncover the underlying role of the genetic
variation in ADD1, subgroup analyses on different diagnostic
standards for hypertension were also carried out.
Sensitivity analyses were conducted by sequential deleting a
single study each time in an attempt to identify the potential
influence of the individual data set to the pooled ORs. In addition,
an estimate of potential publication bias was carried out by the
funnel plot, in which the standard error of log (OR) of each study
was plotted against its OR. An asymmetric plot suggested possible
publication bias. Funnel-plot asymmetry was assessed by the
method of Egger’s linear regression test [19]. Furthermore, we
performed a T-test to determine the significance of the intercept,
and a P value lower than 0.05 was considered to be statistically
significant. HWE was tested by the chi-square test for goodness of
fit based on a Web program (http://www.ihg.gsf.de/cgi-bin/hw/
hwa1.pl).
Analyses were performed using the software Review-Manager
4.2 (Oxford, England) and Stata version 10.0 (Stata Corporation,
College Station, Texas, USA). All P-values were two-sided.
Results
Description of studies identified in meta-analysis
The initial search strategy for hypertension susceptibility related
to the alpha-adducin SNP yielded 152 potentially relevant
references in PubMed and 158 in EMBASE, most of which were
overlapping. In addition, we supplemented the search with a hand
search of reference lists from published literature (117 articles).
After the subsequent screening, 30 studies were identified for
recruitment in the light of the inclusion criteria [6–14,20–40]. All
studies were published between 1997 and 2010. Among the 30
eligible articles, the study of He et al. [14] was replaced by their
latter report [33] which including larger population. Samples
selected were all men (both cases and controls) in Psaty et al. [22]
Only one paper by Province et al. [23] included separate data on
subjects of two ethnicities: European-American and African-
American, however, the genotyping data in the population of
European-American was deviated from HWE (PHWE=0.000522),
ADD1 and Hypertension Risk
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al. [34] (PHWE=0.001644). Thus, those two studies were
excluded. Seven papers did not provide relevant data or the data
provided were not sufficient, we have contacted corresponding or
original authors by e-mail in order to obtain the raw data. Two of
them have replied and offered the necessary data [25,32], and the
other five have not yet responded [35–39]. Furthermore, we also
deleted an article by Marcun Varda et al. [40] that described
hypertension in children and young adults, in which the diagnostic
standard for EH is different from adults [41]. In conclusion, 22
studies were selected for inclusion in our final analyses (Table S1).
All studies used blood sample for genotyping. The flow chart
summarizing the process of study selection and reasons for
exclusion is presented in Figure 1.
Summary statistics
A total of 14303 hypertension patients and 15961 controls were
investigated. Population-based and hospital-based studies were all
included in our meta-analysis. Twelve studies were population-
based [9,13,20,22,23,25–28,30–32], and ten were hospital-based
studies [6–8,10–12,21,24,29,33]. Populations among these studies
were as following: ten studies were Caucasians or European descent
(7632 cases and 8588 controls), nine studies were East Asians (5957
cases and 6770 controls) and three studies were others (one study
Figure 1. Flow chart of selection of studies and specific reasons for exclusion from the meta-analysis.
doi:10.1371/journal.pone.0013057.g001
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recruited African-American subjects) involving 714 cases and 603
controls. All genotypes and allele frequencies of cases and controls
were shown in Table S2. The pooled overall frequency of the Trp
allele were 34.91% and 35.23% in hypertensive cases and in
normotensive controls, respectively. Allele Trp had a higher
representation in cases and controls of East Asians (56.67% and
55.38%, respectively) than that of Caucasians (20.51% and 21.30%,
respectively) and others (7.21% and 7.30%, respectively).
Main results
For each study, we investigated the association between the
alpha-adducin Gly460Trp polymorphism and hypertension risk,
assuming different inheritance models of the 460Trp allele
(Table 1). Overall, when all the eligible studies were pooled into
the meta-analysis, no significant associations between ADD1
Gly460Trp polymorphism and hypertension susceptibility were
observed in all genetic models. No significant associations were
found for allele comparison (Trp vs. Gly: P=0.69, OR=1.02,
95% CI 0.94–1.10, Pheterogeneity,0.0001) (Figure 2a), dominant
genetic mode (GlyTrp+TrpTrp vs. GlyGly: P=0.98, OR=1.00,
95% CI 0.91–1.11, Pheterogeneity=0.0003) (Figure 2b), recessive
genetic model (TrpTrp vs. GlyTrp+GlyGly: P=0.31, OR=1.06,
95% CI 0.95–1.18, Pheterogeneity=0.04) (Figure 2c), and homozy-
gote comparison (TrpTrp vs. GlyGly: P=0.54, OR=1.05, 95%
CI 0.91–1.21, Pheterogeneity=0.01) (Figure 2d). Similarly, no
significant association was detected in all genetic models in the
subgroup analyses by ethnicity and different diagnostic criteria for
hypertension (Table 1).
Sensitivity analysis
Sensitivity analyses were conducted to assess whether each
individual study affected the final results. The findings revealed
that no individual study affected the results in all subjects. In the
subgroup analysis, three independent studies (Cusi et al. [6],
Tamaki et al. [7], and Barlassina et al. [8]) were considered as the
Table 1. Summary estimates for ORs and 95% CI in different subgroups under various genetic contrasts.
Genotype contrasts Study population Study numbers Pheterogeneity P*value OR 95% CI
Allele comparison Overall 22 ,0.0001 0.69
b 1.02 0.94–1.10
(Trp vs. Gly) Caucasian 10 0.001 0.51
b 0.96 0.84–1.09
East Asian 9 0.01 0.19
b 1.06 0.97–1.16
Others 3 0.03 0.90
b 1.05 0.51–2.14
SBP$160, DBP$100 2 0.31 0.62
a 0.98 0.90–1.07
SBP$160, DBP$95 7 0.08 0.38
b 0.94 0.81–1.09
SBP$150, DBP$95 10 ,0.00001 0.61
b 1.05 0.87–1.28
Dominant model Overall 22 0.0003 0.98
b 1.00 0.91–1.11
(GlyTrp+TrpTrp vs. GlyGly) Caucasian 10 0.001 0.56
b 0.96 0.82–1.11
East Asian 9 0.06 0.51
b 1.05 0.91–1.20
Others 3 0.02 0.98
b 1.01 0.45–2.25
SBP$160, DBP$100 2 0.19 0.47
a 0.96 0.87–1.07
SBP$160, DBP$95 7 0.17 0.26
a 0.95 0.87–1.04
SBP$150, DBP$95 10 ,0.00001 0.30
b 1.14 0.89–1.46
Recessive model Overall 22 0.04 0.31
b 1.06 0.95–1.18
(TrpTrp vs. GlyTrp+GlyGly) Caucasian 10 0.28 0.54
a 0.95 0.82–1.11
East Asian 9 0.02 0.13
b 1.10 0.97–1.25
Others 3 0.32 0.69
a 0.80 0.26–2.43
SBP$160, DBP$100 2 0.81 0.76
a 1.04 0.82–1.31
SBP$160, DBP$95 7 0.29 0.24
a 0.90 0.75–1.08
SBP$150, DBP$95 10 0.01 0.67
b 0.94 0.69–1.27
Homozygote comparison Overall 22 0.01 0.54
b 1.05 0.91–1.21
(TrpTrp vs. GlyGly) Caucasian 10 0.16 0.45
a 0.94 0.80–1.10
East Asian 9 0.007 0.23
b 1.12 0.93–1.35
Others 3 0.33 0.65
a 0.77 0.25–2.35
SBP$160, DBP$100 2 0.97 0.88
a 1.02 0.80–1.29
SBP$160, DBP$95 7 0.36 0.33
a 0.91 0.74–1.10
SBP$150, DBP$95 10 0.0005 0.94
b 0.98 0.64–1.52
Abbreviations: OR, odds ratio; CI, confidence interval.
aFixed effect estimate,
bRandom effect estimate.
*The P-value of OR determined by the Z test.
doi:10.1371/journal.pone.0013057.t001
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others, respectively. The three studies were all hospital-based.
After exclusion of these studies, the heterogeneity no longer
existed, but still reached a negative association. (data not shown).
Publication bias
The funnel plot was applied for comparison of 460Trp versus
Gly460 in the OR analysis of alpha-adducin Gly460Trp, and
Egger’s test provided no evidence for funnel-plot asymmetry
(t=20.06, P=0.954) (Figure 3).
Discussion
To the best of our knowledge, this is one of the largest
systematic review of the literature by means of a meta-analysis to
date investigating the association between alpha-adducin
Gly460Trp polymorphism and EH. Compared with the recent
case-control study and meta-analysis by Niu et al. [33], our meta-
analysis conducted here included in total 22 studies with 14303
cases and 15961 controls which were almost three times higher
than the study mentioned above. However, we failed to obtain
association of Gly460Trp polymorphism with hypertension, even
in the stratification analyses based on ethnicity or different
diagnostic criteria.
In 1997, Cusi et al. first reported that 460Trp allele of alpha-
adducin was associated with hypertension in human subjects,
particularly in a salt-sensitive form of EH [6]. Manunta et al.
found that the Gly460Trp polymorphism of ADD1 modulates the
overall capacity of tubular epithelial cells to transport ions through
variations in sodium-potassium ATPase activity and through
modifications in the assembly of the actin cytoskeleton [42].
Further findings indicated a reduced renal pressure-natriuresis
slope after sodium depletion or sodium load in individuals with
Trp allele, which confirmed that humans bearing one Trp allele
alpha-adducin variant displayed an increased of renal tubular
sodium reabsorption and sodium retention [43]. These findings
suggested that 460Trp variant of the a-adducin was probably
associated with a sodium-sensitive form of hypertension, which
was caused by physiology or pathophysiology mechanisms
mentioned above. However, the results of our meta-analysis
showed no significant association between Gly460Trp polymor-
phism and hypertension. It seemed that 460Trp variant was
associated with renal Na
+ handling (sodium transport and
reabsorption) rather than the salt-sensitive form of EH. Among
white hypertensive patients in Italy, five salt sensitivity studies
conducted by BP response to acute salt loading test (saline infusion)
and chronic diuretic treatment effect were performed by the same
research group, which showed evidence to support the role of
460Trp in salt-related hypertension [6,43–46]. Grant et al.
replicated the above result, using a high and low sodium diet
[47], while another study failed to detect this effect in Polish
hypertensives [48]. Turner et al. reported a negative study
involved two ethnicities (African American and non-Hispanic
white), revealing that no relationship existed between a-adducin
genotypes and the BP response to the diuretics [49]. A recent study
by Suonsyrja ¨ et al. showed no influence of Trp allele on the
magnitude of BP fall with diuretics among Finnish hypertensive
men [50]. Taken together with previous results, the impact of
460Trp on diuretics treatment varied among different ethnic and
geographic populations. Results from a newly published meta-
Figure 2. Association between ADD1 Gly460Trp polymorphism and hypertension risk in overall populations under various genetic
contrasts. Figure 2a shows the association between Gly460Trp polymorphism and hypertension in allele comparison (Trp vs. Gly). n indicates the
total number of Trp allele, N indicates the total number of Trp allele plus Gly allele. Figure 2b shows the association between Gly460Trp
polymorphism and hypertension under dominant genetic model (GlyTrp+TrpTrp vs. GlyGly). n indicates the total number of GlyTrp+TrpTrp, N
indicates the total number of individuals. Figure 2c shows the association between Gly460Trp polymorphism and hypertension under recessive
genetic model (TrpTrp vs. GlyTrp+GlyGly). n indicates the total number of TrpTrp, N indicates the total number of individuals. Figure 2d shows the
association between Gly460Trp polymorphism and hypertension in homozygote comparison (TrpTrp vs. GlyGly). n indicates the total number of
TrpTrp, N indicates the total number of TrpTrp plus GlyGly.
doi:10.1371/journal.pone.0013057.g002
Figure 3. Begg’s funnel plot analysis to detect publication bias for allele comparison (Trp vs. Gly). Egger’s test was also performed to
investigate the symmetry of the funnel plot, and no asymmetry was found as indicated by the P value of Egger’s test.
doi:10.1371/journal.pone.0013057.g003
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polymorphism (Gly460Trp) and genetic predisposition to salt
sensitivity suggested that Gly460Trp polymorphism in general is
not significantly associated with salt-sensitivity (P=0.08,
OR=1.40, 95% CI 0.96–2.04) [51]. This was consistent with
our results. However, considering the potential confounders of
studies included in the meta-analysis, our results should be
interpreted with caution.
Furthermore, it is important to highlight that, EH is a complex
polygenic disease responsive to environmental factors. A single
polymorphism or gene likely has weak effects on the individual’s
phenotype, because multiple genes and genetic interactions have
been implicated in the regulation of BP. A family study from van
Rijn et al. [52] showed that the Gly460Trp polymorphism of
ADD1 was able to explain only a very small proportion of the
heritability of BP traits (approximately 0.2% of the SBP variance,
P=0.16; 0.1% of DBP variance, P=0.78; 0.3% of the variance of
pulse pressure, P=0.07). Therefore, it is necessary to explore the
combined effect of Gly460Trp with other related polymorphisms
in the same gene or different genes such as ADD2, ADD3, and
angiotensin-converting enzyme gene (ACE). Lanzani et al.
provided evidence for an epistatic interaction of ADD1 and
ADD3 gene variants was associated with variation in BP among
the hypertensive patients [53]. Another similar study by Staessen
et al. reported that epistatic interaction between the ACE and
ADD1 contributed to the prevalence and incidence of hyperten-
sion in Caucasians [54]. Epistasis is the potentiation or suppression
of a gene by other non-allelic genes [55], which is probably
ignored in the majority of case-control and population studies.
Consequently, the negative findings of studies on the genetic
determinants of EH focused on single-gene effect are not
surprising in these settings. More studies based on larger
population and well-designed, especially studies investigating the
combined effect of Gly460Trp and other polymorphisms are
required to further evaluate the role of these polymorphisms in
hypertension.
Moreover, environmental factors and individual biological
characteristics ought not to be neglected. The former include,
most importantly, salt intake, smoking, alcohol consumption, etc.
For instance, Yamagishi et al. pointed out that the a-adducin
TrpTrp genotype was associated with higher systolic BP among
men with a higher sodium intake [27]. The latter include race,
age, gender, body mass index (BMI), health condition, and general
physiological/neurological functioning, etc. Perhaps most impor-
Figure 4. Forest plot of Gly460Trp polymorphism and hypertension risk on different sample sources for allele comparison. Figure 4a
shows the forest plot of ADD1 Gly460Trp polymorphism and hypertension risk among population-based studies in allele comparison. Figure 4b
shows the forest plot of ADD1 Gly460Trp polymorphism and hypertension risk among hospital-based studies in allele comparison.
doi:10.1371/journal.pone.0013057.g004
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penetrance of genetic variants [56]. Older age increases Na
+
sensitivity, makes the relationship between BP and exchangeable
body Na
+ stronger, reduces renal perfusion, and compromises the
buffering effects of the large arteries on both systolic and diastolic
pressure [56]. On these grounds, comprehensive consideration of
interrelations and interactions with the context of genetic
backgrounds, environmental factors, and individual biological
characteristics is indispensable when exploring the association
between a single gene variant and hypertension risk. Just as
Bianchi et al. mentioned that ‘when context is taken into account,
the impact of adducin in hypertension and its related disorders is
clear’ [57,58].
In the sensitivity analysis, three hospital-based studies (Cusi
et al. [6], Tamaki et al. [7], and Barlassina et al. [8]) were
considered as the main cause of heterogeneity. In order to uncover
the potential influence of the sample sources (population or
hospital-based), further research was conducted on the different
sources of subjects. The results indicated that no heterogeneity was
observed in population-based stuides (Pheterogeneity=0.34,
I
2=10.4%, allele comparison) (Figure 4a), while considerable
heterogeneity existed in hospital-based stuides (Pheterogene-
ity,0.00001, I
2=80.5%, allele comparison) (Figure 4b). There
were still no significant association in the two analyses above. The
controls of the hospital-based studies might be ill-related
population. They might not be a representative of the general
population. Thus, such studies usually have some selection biases,
which might affect the quality and reliability of individual studies.
The results of the present meta-analysis should be interpreted
within the context of its limitations. First, this meta-analysis only
focused on papers published in the English language, so some local
literature biases were inevitable. Second, not all the control
subjects were age- and sex- matched to cases in the studies
included in our meta-analysis, which was likely one of the causes
for heterogeneity. In addition, another potential confounding
effect is that some of the young normotensive controls might
develop hypertension later in their life. Perhaps using stricter
criteria for the selection of normal controls, such as normotensive
subjects aged 55–60 years or older, could exclude the false-
negative controls [59,60]. Third, the strong heterogeneity
observed in the relationship between the Gly460Trp polymor-
phism and hypertension precluded a consistent estimate of the
effect of this variant, even when analyzed by ethnicity.
Furthermore, in our study, we did not perform an evaluation of
potential interactions such as gene-gene, gene-environment, which
might influence the results.
In conclusion, our meta-analysis suggested that the Gly460Trp
polymorphism in ADD1 was not associated with susceptibility to
hypertension even upon stratification by ethnicity or diagnostic
criteria. Based on our discussion and the results from the meta-
analysis, we may conclude that the Gly460Trp polymorphism is
probably not a genetic indicator for increased risk of hypertension.
To better understand the potential mechanism for hypertension in
humans, future research should be carried out to explore the effect
of genetic networks, environmental factors, individual biological
characteristics and their mutual interactions.
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